[go: up one dir, main page]

WO1997013872A1 - Procede pour doser les composes d'amadori - Google Patents

Procede pour doser les composes d'amadori Download PDF

Info

Publication number
WO1997013872A1
WO1997013872A1 PCT/JP1996/002964 JP9602964W WO9713872A1 WO 1997013872 A1 WO1997013872 A1 WO 1997013872A1 JP 9602964 W JP9602964 W JP 9602964W WO 9713872 A1 WO9713872 A1 WO 9713872A1
Authority
WO
WIPO (PCT)
Prior art keywords
sample
amount
solution
faod
measured
Prior art date
Application number
PCT/JP1996/002964
Other languages
English (en)
Japanese (ja)
Inventor
Masayuki Yagi
Fumiyo Funatsu
Toshikatsu Sakai
Kaori Ishimaru
Hiroshi Fukuya
Hiroshi Yoshizu
Katsutaka Oishi
Original Assignee
Kyoto Daiichi Kagaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto Daiichi Kagaku Co., Ltd. filed Critical Kyoto Daiichi Kagaku Co., Ltd.
Publication of WO1997013872A1 publication Critical patent/WO1997013872A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general

Definitions

  • the present invention relates to a method for measuring an Amadori compound using an enzyme, and more particularly to a novel method for measuring an Amadori compound using fructosylamino acid oxidase, and a reagent and a kit used in the method.
  • Amadori compounds are non-enzymatic and irreversible when amino and aldehyde groups coexist with a substance having an amino group such as protein, peptide and amino acid and a reducing sugar such as aldose. It is produced by binding and Amadori rearrangement.
  • the rate of Amadori compound formation is a function of the concentration of the reactive substance, contact time, temperature, and so on. Therefore, it is thought that various information on the substance containing the reactive substance can be obtained from the generation s.
  • Substances containing Amadori compounds include foods such as soy sauce and body fluids such as blood.
  • a fructosylamine derivative which is an Amadori compound in which glucose and amino acid are combined, is produced.
  • a fructosylvanine derivative in which hemoglobin in blood is glycated is called glycohemoglobin
  • a derivative in which albumin is glycated is called glycoalbumin
  • a derivative in which blood protein is glycated is called fructosamine.
  • the decomposition reaction of the Amadori compound by the oxidizing enzyme can be represented by the following general formula.
  • Fructosyl amino acid oxidase Corynebacterium (Japanese Patent Publication No. 5-33997, Japanese Patent Publication No. 6-65300), Aspergillus (Japanese Patent Publication No. 3-155780) 0
  • Fructosyl amino acid-decomposing enzyme enicUliuin (JP-A-4-4874).
  • Ketoamine okidase Corynebacterium S, Fusarium, Acremonium or Debryomyces (Japanese Patent Application Laid-Open No. 5-192193)
  • Alkyl lysinase Prepared by the method described in J. Biol. Chem. 239, pp. 3790-3796 (1964).
  • glycated albumin is produced by the coupling of glucose to the ⁇ -position of a lysine residue in a protein molecule [J. Biol. Chem. 261: 13542-13545 (1986)].
  • glucose is also silicified to the 3-terminal N-terminal variant [J. Biol. Chem. 254: 3892-3 898 (1979)].
  • fructosyl lysine and Z or fructosyl valine in order to measure a glycated protein as an indicator of diabetes.
  • fructosyl lysine cannot be measured accurately by the methods described in JP-B 5-33997 and JP-B 6-65300, and JP-A 3-155780 discloses that glycated protein or its hydrolyzate cannot be measured. The effect is not disclosed.
  • the method described in JP-A-5-192193 cannot accurately measure a glycated protein in which a saccharide is bound to a lysine residue.
  • the Amadori compound (usually a protein) is decomposed into amino acids, and then hydrogen peroxide generated by the reaction of the liberated saccharification site amino acid residues with the enzyme is consumed or consumed. The amount of oxygen needed to be measured and could not be processed quickly. Furthermore, Amadori compounds having different glycation sites could not be specifically measured.
  • the conventional method is not suitable for accurate measurement of glycated protein, and development of a method for rapidly and specifically measuring fructosyl lysine and / or fructosyl valine and a peptide containing at least one of them is awaited.
  • a method for rapidly and specifically measuring fructosyl lysine and / or fructosyl valine and a peptide containing at least one of them is awaited.
  • the present inventors have conducted intensive studies with the aim of providing a measurement method for accurately analyzing an Amadori compound, particularly a glycated protein, and as a result, have found that certain fungi have been identified as fructosyl lysine and / or fructosyl
  • the present inventors have found that the purpose can be achieved by using a nitrogen atom obtained by culturing in the presence of N′—Z-lysine, and completed the present invention.
  • the present invention is characterized in that the measurement is performed using an enzyme. It is intended to provide a method for measuring an Amadori compound in a substance-containing sample.
  • the subject of the method of the present invention is arbitrary, but usually a biological component or food, as long as it can contain the Amadori compound.
  • the Amadori compound is preferably measured by measuring the saccharification rate of the sample, quantifying fructosylamine, or measuring the saccharified substance concentration.
  • analysis of Amadori compounds by measuring the saccharification rate using yeast is novel.
  • measuring Amadori compounds, especially saccharified proteins there are two methods: measuring the absolute amount (concentration) of the saccharified protein and measuring the percentage of saccharified protein (saccharification rate).
  • the total amount of the protein component to be measured and the saccharification amount are separately measured, and the saccharification rate is obtained by calculation. It has great clinical significance.
  • High-performance liquid chromatography, a method using a column packed with solids mixed with boric acid, electrophoresis, and a method using an antigen-antibody reaction include non-glycated tans.
  • the saccharification rate is determined from the relative ratio between the amount of protein and the amount of saccharified protein, there is a disadvantage that information on ft cannot be obtained.
  • this method it is possible to measure the saccharification rate that is important for the diagnosis of diabetes mellitus without being affected by the metabolism and amount of protein, and to determine the nutritional status and the total protein amount for determining the degree of liver injury. Measurement can be performed simultaneously. This indicates that this method is also effective in diagnosing diabetes in patients with diseases involving fluctuations in protein levels.
  • FIG. 1 is a graph showing the relationship between the fructosamine value and the amount of hydrogen peroxide generated by the FAUD action.
  • FIG. 2 is a graph showing the relationship between the concentration of glycated human serum albumin and the amount of hydrogen peroxide generated by the action of FAOD derived from Fusarium oxysvolum S-1F4.
  • FIG. 3 is a graph showing the relationship between the concentration of saccharified human serum albumin and the amount of hydrogen peroxide generated by the action of FAOD derived from Giperella fujikuroi.
  • FIG. 4 is a graph showing the relationship between the concentration of glycated human blood albumin and the amount of purple water peroxide generated by the action of F AOD from Fusarium oxasbum 'f.sp' lini.
  • FIG. 5 is a graph showing the relationship between the concentration of glycated human serum albumin and the amount of hydrogen peroxide generated by the action of FAOD derived from Aspergillus terreus GP1. 2 P
  • FIG. 6 is a graph showing the relationship between the saccharification rate of human serum albumin and the amount of hydrogen peroxide generated by the action of FAOD derived from Fusarium oxasvolum f.sp.lini.
  • FIG. 7 is a graph showing the relationship between the saccharification rate of human serum albumin and the amount of hydrogen peroxide generated by the action of FAOD derived from Aspergillus terreus GP1.
  • Figure 8 is Ru graph der showing the relationship between the amount of hydrogen peroxide generated by the action of FAOD derived from glycation rate and Giperera-fujikuroi of human serum albumin 0
  • FIG. 9 is a graph showing the relationship between the saccharification rate of human serum albumin and the amount of hydrogen peroxide generated by the action of FAOD derived from Fusarium oxysporum S-1F4.
  • FIG. 10 is a graph showing the relationship between the concentration of saccharified hemoglobin and the amount of hydrogen peroxide generated by the action of FAOD derived from Fusarium, oxysporum, f. Sp., And lini.
  • FIG. 11 is a graph showing the relationship between the concentration of saccharified hemoglobin and the amount of hydrogen peroxide generated by the action of FAOD derived from Aspergillus terreus GP1.
  • FIG. 12 is a graph showing the relationship between the amount of saccharified hemoglobin and the amount of hydrogen peroxide generated by the action of FAOD derived from Penicillium jansinerum S-313.
  • FIG. 13 is a graph showing the relationship between the amount of glycated hemoglobin and the amount of hydrogen peroxide generated by the action of FAOD derived from Penicillium jansinerum S-3413.
  • Figure 14 shows valine as a function of total hemoglobin content (absorbance at 415 nm).
  • 4 is a graph showing the relationship between the ratio of saccharification amount (absorbance at 727 nm) and hemoglobin A 1c value.
  • FIG. 15 is a graph showing the relationship between hemoglobin A 1 c value and hydrogen peroxide ft generated by the action of F AOD derived from Penicillium ′ Jansinerum S—34 13.
  • No. 160 shows the relationship between the concentration of fructosylvalin and the amount of hydrogen peroxide produced by the use of FAOD derived from Penicillium 'Jansinerum S-314, detected by a chemical method. It is a graph shown.
  • FIG. 17 is a graph showing the relationship between the concentration of fructosyl lysine and the amount of hydrogen peroxide generated by the action of immobilized FAOD derived from Fusarium 'oxysporum S-1F4.
  • An enzyme that acts on the saccharification site of the substrate includes fructosylamino acid oxidase.
  • fructosylamino acid oxidase When fructosylamino acid oxidase is used, the measurement of the Amadori compound is performed by measuring the amount of oxygen consumed or the amount of a product in the reaction mixture. Products include hydrogen peroxide and glucosone.
  • Quantification of hydrogen peroxide is usually measured using a chromogen that produces a dye upon decomposition of hydrogen peroxide by a catalyst having peroxidase or peroxidase-like activity, or by an electrochemical method. Can be.
  • the amount of hydrogen peroxide generated can be quantified by measuring the amount of aldehyde generated in the presence of catalase and alcohol.
  • an enzyme produced by culturing a fungus in a medium containing fructosyl lysine and Z or fructosyl N "-Z-pyridine can be used.
  • Fructoshi used in the invention method The amino acid oxidase is called FAOD.
  • the FAOD used in the method of the present invention is obtained by culturing a fungus having fructosylamino acid oxidase-producing ability in a medium containing fructosyl lysine and / or fructosyl N'-I-Z-lysine (hereinafter sometimes abbreviated as FZL).
  • FZL fructosylamino acid oxidase-producing ability
  • FZL fructosyl N'-I-Z-lysine
  • FZL fructosyl N'-I-Z-lysine
  • Fusarium oxysporum S-1F4 (Fu_sariuni oxysporum S-1F4) (1-3-1-3 Tsukuba-Higashi, Ibaraki Pref.) Deposited under BP-5010 (Original Deposit: February 24, 1994: Transfer to International Deposit: February 22, 1995), Fusarium Oxysporum f. Sp. Rini (IFO NO 5880) (Fusarium oxysporum f. Sp. Lini), Fusarium oxysporum f. Sp. Batatas (Fusarium oxysporum f. Sp. Batatas) Fusarium oxysporum f. Sp. (IFO NO. 4471) (Fusarium oxysporum f. Sp. Niveuni).
  • Fusarium oxysporum S-1F4 (Fu_sariuni oxysporum S-1F4) (1-3-1-3 Tsukuba-Higashi, Ibaraki Pref.) Deposited under BP-5010 (Original Deposit: February 24, 1994
  • Fusarium oxysporum f. Sp. Kucumulinium (IFO NO. 63 84) Fusarium oxysporum f. Sp. Cucumerinuin, Fusarium xysporum f. sp. melongenae (IFO NO. 7706) (Fusarium oxysporum f. sp. melonge nae), Fusarium oxy Borm ⁇ f. Sp. Avi (IFO NO. 9964) (Fusarium oxysporum f. Sp. Apii), Fusarium 'Oxisborg ⁇ f. Sp. Vinyl (IFO NO. 9971) (Fusarium oxysporum f. Sp.
  • Penicillium cyanium (IFO NO.5337) (Penicillium cyaneum); , Aspergillus' Teleus GP-1 (Contractor: Ministry of International Trade and Industry at the above address; Institute of Biotechnology and Industrial Technology, National Institute of Advanced Industrial Science and Technology; Deposit No .: FERil BP-5684; Deposited by Hara: May 31, 1996; Transfer: September 30, 1996) (Aspergillus terr eus GP-1) Aspergillus oryzae (IFO 4242) (Aspergillus oryzae), Aspergillus oryzae (IF05710) (Aspergillus oryzae), and the like, but are not limited thereto.
  • the FAODs produced by the above method generally catalyze the reaction of oxidizing the Amadori compound in the presence of an acid to produce ⁇ -ketoaldehyde, an amide derivative and hydrogen peroxide.
  • the glucose 01-50% by weight and lysine and / or New beta one ⁇ - lysine 0.01 to 20 wt% in solution 100 Manufactured by autoclaving at ⁇ 150 to 3-60 minutes.
  • New beta one Zeta - dissolved lysine emissions 10 g, usually 120. C can be manufactured by autoclaving for 20 minutes.
  • FZL medium may be prepared by adding fructosyl lysine and FZL or FZL obtained by the above method to an ordinary medium, for example, by adding 0.01 to 50% by weight of glucose, / or New beta - zeta-lysine 0.01,20 weight 3 ⁇ 4, K 2 HP0 4 0.1 wt%, NaH 2 P0 4 0.1 wt%, MgS0 4 ⁇ 7H 2 0 0.05 wt%, CaC 1 2 ⁇ 2 ⁇ 2 0 0.01 weight % And yeast extract 0.2% by weight (preferably ⁇ 5.6-6.0) can be obtained by subjecting the mixture to autoclaving at 100 to 50 L for 3 to 60 minutes.
  • the medium used for the production of FAOD used in the method of the present invention may be an ordinary synthetic or natural medium containing a carbon source, a nitrogen source, an inorganic substance, and other nutrient sources.
  • a carbon source include glucose.
  • a nitrogen source peptone, casein digest, yeast extract, etc. can be used.
  • inorganic substances those contained in ordinary culture media such as sodium, potassium, calcium, manganese, magnesium, and cobalt can be used.
  • FAOD used in the method of the present invention is most induced when cultured in a medium containing fructosyl lysine and F or FZL.
  • a medium containing fructosyl lysine and F or FZL examples of preferred media, the FZL obtained by the method described above as a single nitrogen source, FZ L medium (1.0% glucose using glucose as the carbon crowd source, 0.5% FZL, 0.1% K Z HPO "0 . l% NaH 2 P0 4, 0.05% MgS0 4 ⁇ 7H 2 0, 0.01% C a C 12 ⁇ 2H 2 0 and 0 ... 0.01% vitamin mixture) can Rukoto cited.
  • the FZL medium can be prepared by adding FZL to a normal medium or by autoclaving a medium containing glucose and! ⁇ '-Z-lysine.
  • Culturing is usually performed at about 25 to 37, preferably at 28.
  • the ⁇ of the medium is in the range of 4.0 to 8.0, preferably 5.5 to 6.0.
  • these conditions are those which are appropriately polished in accordance with the condition of each bacterium, and are not limited to the above.
  • the tie obtained in this manner can remove nucleic acids, cell wall fragments, and the like according to a conventional method to obtain an enzyme product.
  • the disruption of the cells may be any of autolysis, freezing, sonication, and pressurization using mechanical means or a solvent.
  • Methods for separating and purifying yeast cord include a combination of salting out using ammonium sulfate or the like, precipitation with an organic solvent such as ethanol, ion exchange chromatography, hydrophobic chromatography, gel filtration, and affinity chromatography. Make some.
  • the culture tie is collected by centrifugation or suction filtration to collect mycelium, washed, made 0.1 M Tris-HCl buffer ( ⁇ 8. ⁇ ), and crushed by Dyno-llill.
  • the supernatant obtained by centrifugation is treated as a cell-free extract by ammonium sulfate fractionation and fluorosepharose monofiltration. To purify.
  • the FAOD used in the method of the present invention regardless of the degree of purification, is not limited to enzyme-containing substances in all purification stages, including culture medium, as long as it can catalyze the oxidation reaction of Amadori compounds. Solution.
  • the present invention can achieve the object of the present invention only at the site of the fermented purple molecule that is involved in the activity of the enzyme. Therefore, the present invention also encompasses any fragment having the oxidation activity of the Amadori compound.
  • the FAOD thus obtained is useful not only for the measurement of Amadori compounds, especially for the measurement of glycated proteins for the diagnosis of diabetes, but also for solving the technical problems to be solved by the present invention. It is.
  • an enzyme obtained by culturing a living organism transformed by an expression vector containing a DNA encoding FAOD can also be used in the method of the present invention.
  • the FAOD thus obtained is useful not only for the measurement of Amadori compounds, particularly for the measurement of glycated proteins for the diagnosis of diabetes, but also for the technical problems to be solved by the present invention. Useful.
  • the characteristics of the FAOD used in the method of the present invention will be described in detail. 1.
  • FAOD used in the method of the present invention is an inducible enzyme induced by fructonyl lysine and / or FZL.Fructosyl lysine and / or FZL is used as a nitrogen source and glucose is used as a carbon source. It is produced by culturing fungal fructosylamino acid oxidase-producing bacteria.
  • FAOD is induced in a GL browning medium obtained by autoclaving both glucose and lysine and / or N'-Z-lysine. Prepared by toraping 3 ⁇ 4enzyme acts specifically on the Amadori compound, since it is not induced in the cultivated medium.
  • FAOD used in the method of the present invention has the formula:
  • R 1 represents an aldose residue
  • R 2 represents an amino acid, protein or peptide residue
  • R 1 is —OH, one (CH 2 ) casual— or one [CH (OH)] n-CHzOH (where n is an integer of 0-6)
  • R 2 is —CHR
  • Amadori compounds represented by 3 — [CONHR 3 ] n COOH (wherein, R 3 is a residue on one amino acid side and m is an integer of 1 to 480) are preferred as the substrate, among which R 3 is lysine And a side residue of an amino acid selected from boryridine, parin, asparagine, etc., and a compound wherein n is 5 to 6 and m is 55 or less.
  • Table 1 is —OH, one (CH 2 ) argue— or one [CH (OH)] n-CHzOH (where n is an integer of 0-6)
  • R 2 is —CHR
  • Amadori compounds represented by 3 — [CONHR 3 ] n COOH (wherein, R 3 is a residue on one amino acid side and m is an integer of 1
  • Table 1 shows that F AOD used in the method of the present invention has high specificity for fructosyl lysine and / or fructosyl valine. Further, the activity of FAOD for each substrate is shown in Table 2 below.
  • FAOD used in the method of the present invention has activity against fructosyl lysine and Z or fructosyl boryl lysine, which indicates that the FAOD is useful for measuring glycated albumin. It indicates that there is.
  • FAODs derived from Fusarium oxysvolum.f.sp.'lini, Aspergillus'Teleus GP1 and Penicillium jansinerum S-3413 used in the method of the present invention have activity against fructosylvalin. This indicates that the FAOD is also useful for measuring glycated hemoglobin.
  • FAOD used in the method of the present invention also has an activity on protease digests of glycated proteins.
  • the power grinding measurement of the bran was performed by the following method.
  • the 10 OmM FZL solution was prepared by dissolving FZL obtained in advance with distilled water. 45 mM 4-Aminoantipyrine, 60 units / m 1 peroxidase solution, 100/1 each of 6 OmM Fuunol solution, 0.1 M Tris-HCl ⁇ mouth solution (pH 8.0) Im and »3 ⁇ 4 solution 51 Mix and make up to 3.0 ml with distilled water. After incubating for 2 minutes at 30 ° C., 501 OmM solution was added, and the absorbance at 505 nm was measured over time.
  • the present invention provides a method for measuring oxygen consumption or a reaction product by bringing a sample containing an Amadori compound into contact with FAOD.
  • Another object of the present invention is to provide a method for measuring an Amadori compound in a sample. The method of the present invention is carried out based on the measurement of the amount and / or saccharification rate of a glycated protein in a biological component or food, or the determination of fructosylamine.
  • the enzyme activity of FAOD is measured based on the following reaction.
  • R 1 represents an aldose residue
  • R 2 represents an amino acid, protein or peptide residue
  • test liquid use any sample solution containing the Amadori compound.
  • sample solution containing the Amadori compound examples thereof include foods such as blood (whole blood, blood serum or serum), urine and other biological samples, as well as oils.
  • any of the following methods for measuring an Amadori compound is used.
  • the action of FAOD produces hydrogen peroxide and glucosone.
  • Hydrogen peroxide is measured by a method known in the art, for example, a coloring method, a method using a hydrogen oxide electrode, etc., and a standard curve prepared for the amounts of water peroxide purple and the Amadori compound.
  • the Amadori compound in the sample is measured by comparing with. Specifically, it is based on the measurement of the titer described in 3 above. However, the amount of FAOD shall be 1 unit Zm 1, an appropriately diluted sample shall be added, and the amount of hydrogen peroxide generated shall be measured.
  • the color development system for the colorimetric method of hydrogen peroxide is as follows: ⁇ ⁇ ⁇ Couplers such as 4-aminoantivirin (AAA) and 3-methyl-12-benzothiazolinone hydrazone (MBTH) in the presence of oxidase. It is possible to use a system that produces a dye by oxidative condensation of phenol with a chromogen such as phenol.
  • chromogens include fuynol derivatives, aniline derivatives, and toluidine derivatives.
  • a leuco-type coloring reagent which is oxidized in the presence of peroxidase to give a color
  • Various leuco-type coloring reagents are known to those skilled in the art, and include 0-dian ginseng, 0-trizine, 3.3-diaminobenzidine, 3,3.5.5-tetramethylbenzidine, and N- (carboxymethylaminocarbonyl). And 1,4-bis (dimethylamino) biphenylamine (DA64), 10- (carboquinmethylaminocarbonyl) -1,3,7-bis (dimethylamino) phenothiazine (DA A67), and the like.
  • the measurement of hydrogen peroxide using a chromogen includes a colorimetric method, a luminescence method, and a chemical luminescence method.
  • a compound that emits fluorescence by oxidation for example, homovanillic acid, 4-hydroquinphenyl sulfonic acid, tyramine, nociclecresol, diacetylfluorescin derivative and the like can be used.
  • chemiluminescence method veroxidase, lithium furocyanide, hemin, or the like can be used as a catalyst, and luminol, noresigenin, isorminol, pyrogallol, or the like can be used as a substrate.
  • a system in which catalase is allowed to act in the presence of an alcohol (eg, methanol) and the resulting aldehyde is colored by a Hunch reaction or a condensation reaction with MBTH can be used.
  • This aldehyde can also be conjugated to aldehyde dehydrogenase to measure changes in NAD (NADH).
  • an aldose reagent such as diphenylamine can be used.
  • the anode When measuring hydrogen peroxide using an electrode, the anode can be any material that can transfer electrons to and from hydrogen peroxide, but platinum, gold, silver, etc. are preferred. .
  • the measurement can be performed by a method known to those skilled in the art, such as ambiometry, potentiometry, and coulometry.
  • the reaction between the FAOD or the substrate and the positive electrode is mediated by an electron carrier, The resulting oxidation or reduction current or the amount of electricity can also be measured.
  • the electron conductor may be a substance known to those skilled in the art, such as a fluorinated conductor, a quinone derivative, or any substance having an electron transfer function that can be generally considered by those skilled in the art.
  • a proton conductor can be interposed between the hydrogen peroxide generated by the FAD reaction and the electrode, and the resulting oxidation, a-source current, or its air volume can be measured.
  • the value obtained by subtracting the amount of oxygen at the end of the reaction from the amount of oxygen at the start of the reaction is measured and compared with the quasi-curve created for the amounts of oxygen quenched Si and Amadori compounds in the sample. Is measured. Specifically, the measurement is performed in accordance with the above-mentioned titration measurement. However, the amount of F A O D to be used shall be 1 unit / ml, and an appropriately diluted sample shall be added to determine the amount of oxygen eliminated.
  • the method of the present invention can be carried out using the sample solution as it is, depending on the target Amadori compound, it is preferable to carry out the sample while or after the sample is treated so that the FAOD reacts.
  • Such purposes include the use of protease (enzymatic method), the use of chemicals such as trifluorosulfuric acid (chemical method), and the use of physical methods such as heat (physical method).
  • protease enzymatic method
  • chemical method the use of chemicals such as trifluorosulfuric acid
  • physical method such as heat (physical method).
  • endo- and exo-type proteases known to those skilled in the art can be used alone or in combination.
  • Endo-type proteases are abundant substances that are degraded from the inside of proteins.
  • the exo-type Oral protease is an enzyme that decomposes sequentially from the end of the peptide chain, and examples thereof include aminopeptidase and carboxypeptidase. Enzyme treatment methods are also known and can be performed, for example, by the method described in the following Examples.
  • endo-type and exo-type proteases are preferably used depending on the saccharification site of the Amadori compound to be measured by utilizing its properties.
  • glycated albumin is an endo-type protease because the internal lysine residue is glycated
  • hemoglobin Ale is an exo-type protease because the / 9 chain N-terminal valine residue is glycated. Processing can be performed more efficiently.
  • Proteinase A 5.0 200 Subtilisin ⁇ .7 230 Human cathepsin 4.2 170 Protease XIV 7.7 310 Bronase 5.8 230 Bronase E 8.4 340 Proteinase K 3.1 120 Blotase P 3.0 120 Blotase N 4.4 180 Proleather 3.0 120 Papain 5.0 200 Protease A 5.9 240 Bromelain F 4.0 160 exo-type protease
  • Carboxypeptidase B 1.27 33.3 Aminopeptidase 3.82 100.0 Aminobutidase M 0.43 11.2 Furthermore, according to the method of the present invention, unlike the conventional method, it is not necessary to completely decompose the Amadori compound into amino acids and release saccharified amino acid residues in the treatment by the thixotropy method. The processing time can be shortened because the saccharified peptide may be in a state in which FAOD can easily react.
  • an acid, an alkali, a surfactant, a protein denaturant and the like can be used alone or in combination.
  • heat, microwave, pressure, etc. can be used alone or in combination.
  • the enzymatic method, the chemical method, and the physical method can be used alone, but may be used in an appropriate combination. Further, these processes can be performed before or at the time of the F AOD reaction.
  • the processing of the sample and the FAOD reaction can be performed simultaneously, so the operation is simpler and more labor-intensive than the conventional method. Instead, it can be measured in a short time.
  • FAOD used in the method of the present invention since FAOD used in the method of the present invention has high substrate specificity for fructosyl lysine contained in glycated proteins, it includes the measurement of glycated albumin in a blood sample, diagnosis of diabetes, etc. Useful for In addition, since fructosylvaline also has specificity, it is useful for measuring hemoglobin A1c.
  • the collected blood sample is used as it is or after being subjected to a treatment such as folding.
  • the sample is a whole blood or hemolyzed sample
  • the sample will show a unique absorption spectrum due to the presence of hemoglobin.
  • the wavelength to be detected overlaps with the absorption of hemoglobin, and accurate measurement cannot be performed. Therefore, it is necessary to subtract the previously measured hemoglobin spectrum from the spectrum after the FAOD reaction and measure the difference.
  • this method is not always accurate, and is cumbersome.
  • the absorption of hemoglobin itself can be avoided, and the measurement can be performed in a long wavelength region (600 to 800 nm), whereby the shadow of hemoglobin in the sample can be obtained. And more accurate measurement is possible.
  • hydrogen peroxide produced by the action of FAOD was produced by oxidative coloring of DA64, DA67, 4AA / MAOS, 4AAZM APS, etc. in the presence of peroxidase, and by the action of lipase. It is detected by color development due to the condensation reaction between aldehyde and MBTH.
  • glycated albumin as well as Amadori compounds containing hemoglobin Ale in whole blood and hemolyzed samples can be measured.
  • the detection wavelength is not limited to this, and even if it is in the wavelength range that overlaps with hemoglobin absorption, as described above, the previously measured hemoglobin spectrum is measured after the FAOD reaction.
  • the method of subtracting from the spectrum and measuring the difference is also included in the method of the present invention.
  • the enzymes such as FAOD, peroxidase, lipase, and protease used in the method of the present invention may be used in the form of a solution, or may be immobilized on a suitable solid support.
  • a suitable solid support for example, by packing an enzyme immobilized on beads into a column and incorporating it into an automated device, routine analysis of a large number of samples such as clinical tests can be performed efficiently.
  • the immobilized yeast purple can be reused, which is preferable in terms of economic efficiency.
  • Immobilization of the enzyme can be performed by a method known in the art.
  • the method is carried out by a carrier binding method, a cross-linking method, an inclusive method, a complex method, or the like.
  • Carriers include polymer gels, microcapsules, agarose, alginic acid, and carrageen One Nan, and so on. Coupling is performed by a method known to those skilled in the art using covalent bonding, ionic bonding, physical adsorption, and biochemical affinity.
  • the analysis may be either flow or batch.
  • immobilized enzymes are particularly useful for routine analysis (glycos) of glycated proteins in blood samples.
  • the result should be expressed as glycated protein concentration, the ratio of glycated protein concentration to the total protein K concentration in the sample (glycation rate), or fructosylamine 4. .
  • the total protein concentration can be determined by a conventional method known to those skilled in the art (eg, absorbance at 280 ⁇ , Bradford method, Lowly method, Buret method, etc.). If the Amadori compound (glycated protein) to be measured is glycated albumin, phthalein dyes such as bromcresol green (BCG), bromcresol monopurple (BCP), and bromphenol blue (BPB) are used for the total albumin S level.
  • BCG bromcresol green
  • BCP bromcresol monopurple
  • BBPB bromphenol blue
  • methyl orange a method using azo dyes such as 2- (4'-hydroquinbenzenazo) benzoic acid (HAB (C) A), nephrometry, a method using the natural fluorescence of albumin, etc.
  • HAB (C) A 2- (4'-hydroquinbenzenazo) benzoic acid
  • nephrometry a method using the natural fluorescence of albumin, etc.
  • the measurement target is glycated hemoglobin
  • the total hemoglobin concentration can be measured by a gas method, a cyanmethemoglobin method, an azamethemoglobin method, a method using the absorbance of hemoglobin itself, etc.
  • the present invention is not limited to this.
  • the present invention also provides a method for measuring an Amadori compound in a sample, comprising: FAOD; and a processing reagent for treating the sample such that a saccharification site of the Amadori compound in the sample reacts with FA0D to form a sieve. It provides a reagent or kit.
  • FAOD jt in reagents is usually 1 to 1 per sample. 100 nits / ml, and the buffer solution is preferably Tris-HCl (pH 8.0).
  • the color-forming system may be a system that forms a color by oxidative condensation described in the above-mentioned “(1) Method based on the amount of reaction product”, or a leuco-type.
  • a coloring reagent or the like can be used.
  • a kit can also be obtained by combining the reagent for measuring the Amadori compound of the present invention, an appropriate color former, and a color standard or standard substance for ratio. Such a kit would be useful for preliminary diagnosis and testing.
  • the above measuring reagents and kits are used for measuring the amount and / or saccharification rate of glycated protein in biological components or foods, or for quantifying fructosylamine.
  • Production example 1 Production of FAOD derived from Giperella
  • Gibberella fujikuroi (IFO NO.6356) (Gibberella fujikuroi) from FZL 0.5%, glucose 1.0%, diphosphoric acid 0.1%, phosphoric acid-sodium 0.1%, magnesium sulfate 0.05%, calcium chloride 0.01%
  • the cells were inoculated into 10 L of a medium (pH 6.0) containing 0.2% yeast extract, and cultured with stirring using a jar fermenter with aeration of 2 LZ for 28 hours at a stirring speed of 400 rpm. Cultures were collected over time.
  • Ammonium sulfate was added to the obtained supernatant to 75% saturation, stirred, and centrifuged at 12.00 Orpm for 10 minutes.
  • Precipitate contains 2 mM DTT was dissolved in 50 mM Tris-HCl buffer (pH 8.5) (buffer A) and dialyzed against buffer A overnight.
  • the dialysate was adsorbed on a DEAE-Sephacel column equilibrated with buffer A. After washing with buffer A, elution was performed with a linear gradient of 0-0.5M potassium chloride.
  • the active fraction was collected, subjected to a 55% to 75% ammonium sulfate fraction, and dialyzed against buffer A.
  • Ammonium sulfate was added to the dialysate so as to be 25% saturated, and the dialysate was adsorbed to a full-length Yopearl column equilibrated with buffer A containing 25% saturated ammonium sulfate. After washing with the same buffer, elution was carried out with a linear gradient of ammonium sulfate concentration of 25-0% saturation. The active fractions were collected, ammonium sulfate was added to achieve 40% saturation, and the mixture was adsorbed on a Petit Root Yopal column equilibrated with buffer A containing 40% saturated ammonium sulfate.
  • Fusarium oxisbolum S-1 F4 (FERM BP-5010) (Fusarium ox ysporum S-1F4) was prepared from FZL 0.5%, glucose 1.0%, dicalcium phosphate 0.1%, monosodium phosphate 0.1%, magnesium sulfate Inoculate 10 L of a medium (pH 6.0) containing 0.05%, 0.01% calcium chloride and 0.2% yeast extract, and use a jar armor for 2 minutes with a stirring speed of 40 Orpm. The culture was agitated for hours. Cultures are collected by filtration. I did.
  • a portion (200 g) of the mycelium was suspended in 1 L of 0.1 M Tris-monohydrochloride buffer (pH 8.5) containing 0-chome, and the mycelium was disrupted by Dyno-Mill.
  • the crushed liquid was centrifuged at 10,000 Orpn for 15 minutes, and the obtained liquid was used as a crude enzyme liquid (cell-free extract).
  • Ammonium sulfate (hereinafter abbreviated as ammonium sulfate) was added to the crude enzyme solution so as to be 40% saturated, and the mixture was stirred and separated at 12.00 Orpin for 10 minutes. Ammonium sulfate was added to the obtained supernatant to 75% saturation, stirred, and eccentrically separated at 12.00 Orpin for 10 minutes.
  • the precipitate was dissolved in 50 mM Tris-HCl buffer (pH 8.5) containing 2 mM DTT (hereinafter abbreviated as buffer A), and dialyzed against mouth liquid A overnight.
  • the dialysate was adsorbed on a DEAE-Sephacel column equilibrated with buffer A. After washing with the same buffer A, elution was carried out with a linear concentration gradient of 0 to 0.5 M potassium chloride.
  • the active fraction was collected, subjected to a 55% to 75% ammonium sulfate fraction, and dialyzed against buffer A overnight.
  • Ammonium sulfate was added to the dialysate so as to be 25% saturated, and the dialysate was adsorbed to a Fuyroot yopal column equilibrated with buffer A containing 25% saturated ammonium sulfate. After washing with the same buffer solution, elution was performed with a linear gradient of 25-0% saturation. The active fractions were collected, ammonium sulfate was added to 40% saturation, and the mixture was adsorbed on a Petil-Toyopearl column equilibrated with Buffer A containing 40% saturated ammonium sulfate. After washing with the same buffer, elution was carried out with a linear concentration gradient of ammonium sulfate S degree 40-0% saturation.
  • the active fractions were collected, ammonium sulfate was added to 80% saturation, and the mixture was stirred, centrifuged at 12.000 rpm for 10 minutes, and the obtained precipitate was dissolved in 0.1 M buffer A.
  • the enzyme solution was applied to a Cefacryl S-200 gel filtration chromatograph which had been equilibrated with 0.1 M buffer A and contained 0.1 M of chloride.
  • Active fractions were collected and concentrated by ultrafiltration. Treating the concentrate with a Pharmacia FPLC system using a Mono Q column (0-0.5 M linear chlorinated chloride using buffer A, elution with a gradient), 30-60 units To obtain a purified mellow purple.
  • Fusarium 'oxysporum f.sp.lini IFO .5880
  • CFusarium oxysporum f. Sp. Lini or Aspergillus terreus GP 1 (FERM BP-5684)
  • Aspergillus terreus GP1 0.5% FZL, glucose 1.
  • Medium containing 0%, 0.1% dipotassium phosphate, 0.1% monosodium phosphate, 0.05% magnesium sulfate, 0.01% calcium chloride, and 0.2% yeast extract (pH 6. 0) 10 L was inoculated and cultivated with a jar arm for 28 hours under the conditions of an aeration amount of 2 LZ and a stirring speed of 40 Orpa for 28 hours.
  • the tie stuff was collected after a.
  • Step 1 Ammonium sulfate fractionation
  • ammonium sulfate (hereinafter abbreviated as ammonium sulfate) was added to the crude enzyme solution so that it became 40% saturated, and the protein was removed by centrifugation (4 EC . 12.00 ⁇ ). Further, ammonium sulfate was added to the supernatant so as to be 75% saturated, and the precipitate was recovered.
  • Step 2 Hydrophobic chromatography (batch method)
  • the precipitate obtained in Step 1 is dissolved in 5 OmM Tris-monohydrochloride buffer (pH 8.5) containing 2 mM DTT (hereinafter abbreviated as buffer A) and contains an equal amount of 40% ammonium sulfate Quench A was added. 200 ml of butyl-TOYOP EARL resin was added to the crude enzyme solution, and adsorption was performed by the batch method. Elution was also performed by the batch method using buffer A, and the active fraction was sulfuric acid. The solution was concentrated by precipitation.
  • the concentrated active fraction was adsorbed to a phenyl-TOYOPEARL column equilibrated with buffer A containing 25% ammonium sulfate, washed with the same buffer, and eluted with a linear gradient of 25 to 0% ammonium sulfate. .
  • the collected active fraction was concentrated by ammonium sulfate precipitation and used for the next step.
  • Step 4 Hydrophobic chromatography (column method)
  • the collected active fraction was used for a butyl topopearl column (equilibrated with mouth liquid A containing 40% ammonium sulfate).
  • the concentrate was adsorbed and washed with the same buffer.
  • the active fraction was obtained with a linear gradient of 40 to 0% ammonium sulfate.
  • Step 5 ion exchange mouth chromatography
  • Benzinlium Jansinerum S-3413 (FERM BP-5475) (Penicill iuB janthinellum S-3413) was prepared from 0.5% FZL, 1.0% glucose, 0.1% dibasic phosphate, 0.1% sodium phosphate, 0.1% magnesium sulfate, magnesium sulfate Inoculated in 10 L of a medium (pH 6.0) containing 0.05% calcium chloride, 0.01% calcium chloride, and yeast extract 0.2%. The mixture was cultured for 28 to 36 hours under conditions of a flow rate of 2 LZ and a stirring speed of 50 Orpm. Cultures were collected over time.
  • Ammonium sulfate (hereinafter abbreviated as ammonium sulfate) was added to the crude enzyme solution so as to be 403 ⁇ 4 saturated, stirred, and centrifuged at 12.00 Orp for 10 minutes. Ammonium sulfate was added to the obtained supernatant to 75% saturation, stirred, and eccentrically separated at 12. ⁇ for 10 minutes.
  • the precipitate was dissolved in a 5 OmM calcium phosphate buffer (pH 7.5) containing ImM DTT (hereinafter referred to as buffer A).
  • the obtained solution was dialyzed against buffer A.
  • the external solution was exchanged twice.
  • the enzyme solution after the analysis was ablated on a DEAE-Sephacel column (4.226 cm) equilibrated with buffer A.
  • the active fraction was found in the fraction washed with the same buffer, and was collected and subjected to ammonium sulfate fraction of 0-55% saturation. Next, the enzyme was equilibrated with buffer A containing 25% saturated ammonium sulfate.
  • fructosyl polylysine solution 0.1% fructosyl polylysine solution was analyzed using the BMY / NBT assay. Test showed a fructosamine value of 750 ol / 1.
  • the FAOD reaction solution was prepared as follows.
  • the 7.6 unit ZmlF AOD solution was prepared using 0.1 M Tris-hydrochloric acid buffer (pH 8) so that the FAOD derived from Giperella fujikuroi (IFO NO. .0) to make silk.
  • Figure 1 shows the relationship between the fructosamine value and the absorbance obtained by this method.
  • the vertical axis represents the absorbance at 505 mn (corresponding to the amount of hydrogen peroxide)
  • the horizontal axis represents the fructosamine value. The figure shows that the fructosamine value and the amount of generated hydrogen peroxide are correlated.
  • FAOD derived from Fusarium obtained in Production Example 2 was used.
  • Glycated human serum albumin (Sigma) is dissolved in 0.9% sodium chloride aqueous solution. Then, saccharified human serum albumin solutions having different concentrations in the range of 0 to 10% were prepared.
  • the F A 0 D reaction solution was prepared as follows.
  • Fig. 2 shows the relationship between the concentration of saccharified albumin obtained by this method and the absorbance.
  • the vertical bar in the figure indicates the absorbance of 555 ⁇ (corresponding to the amount of hydrogen peroxide), and the horizontal axis indicates the concentration of glycated albumin. The figure shows that the concentration of saccharified albumin and the amount of hydrogen peroxide generated are correlated.
  • Example 2 the same operation as in Example 2 was repeated, except that the FAOD derived from Giperella II obtained in Production Example 1 was used.
  • the FAOD solution was prepared by mixing FAOD derived from Gibberella fujikuroi obtained in Production Example 1 (IFO No. 6356) (Gibberella fujikuroi) with 0.1 M Tris-hydrochloric acid buffer (pH 8. 0).
  • Figure 3 shows the relationship between the concentration of saccharified albumin (horizontal axis in the figure) and absorbance (corresponding to hydrogen peroxide i: vertical axis) obtained by this method.
  • the figure shows that the concentration of saccharified albumin and the amount of generated hydrogen peroxide are correlated.
  • Example 3 the same operation as in Example 2 was repeated, except that the FAOD derived from Fusarium ⁇ obtained in Production Example 3 was used 50 // 1.
  • the FAOD solution was prepared so that the FAOD derived from Fusarium 'oxysbolum ⁇ f.sp. ⁇ lini (IFO NO.5880) (Fusariura oxys orum f.sp. lini) obtained in Production Example 3 was 6.0 units Zml. It was prepared by diluting with 0.1 M Tris-HCl buffer (pH 8.0).
  • Figure 4 shows the relationship between the concentration of saccharified albumin (horizontal axis in the figure) and the absorbance (corresponding to the amount of hydrogen peroxide: vertical bow) obtained by this method.
  • the figure shows that the concentration of saccharified albumin and the amount of generated hydrogen peroxide are correlated.
  • the D solution was prepared such that the FA D derived from Aspergillus terreus GP1 CFEB1I BP-5684 (Aspergillus terreus GP1) was adjusted to 0.1 units / ml.
  • the product was diluted with M Tris-hydrochloride mouth liquid (pH 8.0) and manufactured by IS.
  • Figure 5 shows the relationship between the concentration of saccharified albumin obtained by this method (horizontal axis in the figure) and the absorbance (corresponding to the amount of hydrogen peroxide: vertical axis). The figure shows that the concentration of saccharified albumin and the amount of generated hydrogen peroxide are correlated.
  • the F A 0D reaction solution was subjected to ISSi as follows.
  • the 6 unit / ml FAOD solution was prepared by converting FAOD from Fusarium oxysporum f.sp. lini (Fusarium oxysporum f. Sp. Lini) obtained in Production Example 3 to 6 unit Znl. It was prepared by diluting with 0.1 M Tris-HCl buffer (pH 8.0).
  • FIG. 6 shows the relationship between the saccharification rate of albumin obtained by this method and the absorbance.
  • the vertical axis in the figure indicates the absorbance of 555na (corresponding to the amount of hydrogen peroxide), and the horizontal axis indicates the saccharification rate of albumin.
  • the figure shows that the saccharification rate of albumin and the hydrogen peroxide generator are in a relationship.
  • the same operation as in Example 6 was repeated, except that the FAO D derived from Alpergillus ⁇ obtained in Production Example 3 was used.
  • the FAOD solution is prepared by diluting FAOD derived from Aspergillus' Teleus GP1 (FERM BP-5684) (Aspergillus terreus GP1) with 0.1 Tris-HCl buffer (pH 8.0) to 6.0 nit / ml. IS made.
  • Figure 7 shows the relationship between the saccharification rate of albumin (horizontal axis in the figure) and absorbance (corresponding to the amount of hydrogen peroxide: vertical axis) obtained by this method.
  • the figure shows that the saccharification rate of albumin and the amount of generated hydrogen peroxide are correlated.
  • the FAOD derived from Giperella ⁇ obtained in Production Example 1 was used for 201 The same operation as in Example 6 was repeated, except that it was performed.
  • the FAOD solution was prepared using 0.1 M Tris-HCl buffer (pH 8) such that the FAOD from Giperella fujikuroi (IFO No. 6356) (Gibberella fu jikuroi) obtained in Production Example 1 was adjusted to 6.6 units / m1. .0) and prepared.
  • Fig. 8 shows the relationship between the saccharification rate of albumin obtained by this method (jux axis in the figure) and absorbance (corresponding to the appropriate amount of oxidized water purple: vertical axis). The figure shows that the saccharification rate of albumin and the amount of generated hydrogen peroxide are correlated.
  • Example 2 the same operation as in Example 6 was repeated, except that 201 of the Fusarium-derived FA0D obtained in Production Example 2 was used.
  • the FAOD solution was prepared so that the FAOD derived from Fusarium oxisbolum S-1F4 (FERH BP-5010) (Fusarium o ysporum S-1F4) obtained in Production Example 2 was 10.3 units.
  • the mixture was diluted with 1M Tris-HCl buffer (pH 8.0) and made into an air-tight.
  • Figure 9 shows the relationship between the saccharification rate of albumin obtained by this method (figure ⁇ in Fig. ⁇ ) and absorbance (corresponding to the amount of peroxidized water: vertical axis). The figure shows that there is a correlation between the concentration of saccharified albumin and the amount of hydrogen peroxide generated.
  • Fusarium-derived FAOD obtained in Production Example 3 was used.
  • Glycohemoglobin control Sigma was dissolved in distilled water to prepare glycated hemoglobin solutions having different concentrations in the range of 0 to 30%.
  • Glycated hemoglobin solution 2 500 units / 101 aminopeptidase (Exo-type mouth opening) Solution 5 1
  • Tris-HCl buffer pH 8.0 20 ⁇ 30 Incubated at C for 30 minutes. Thereafter, 50% acetic acid at 10% trichloro mouth was added and the mixture was stirred. The mixture was kept at 0 ° C for 30 minutes and centrifuged at 1200 Orpn for 10 minutes. About 50 l of 2M NaOH was added to the obtained supernatant to make a neutral solution.
  • the F A 0 D reaction solution was prepared as follows.
  • the 4-unit / ml FAOD solution was prepared by combining the FAOD derived from Fusarium oxyspornolem, f.sp., lini (IFO NO.5880) (Fusarium oxysporum f.sp. lini) obtained in Production Example 3 with 4 units / ml. It was prepared by diluting with a 0.1 M Tris-monohydrochloride buffer solution (pH 8.0).
  • FIG. 10 shows the relationship between the concentration of saccharified hemoglobin and the absorbance obtained by this method.
  • the vertical axis in the figure represents the absorbance at 727 nm (corresponding to the amount of hydrogen peroxide), and the horizontal axis represents the concentration of glycated hemoglobin.
  • the figure shows that the degree of glycated hemoglobin and the amount of generated hydrogen peroxide are correlated.
  • Example 11 Measurement of saccharified hemoglobin concentration
  • the same operation as in Example 10 was repeated, except that FA 0D derived from Arlbergills JR obtained in Production Example 3 was used. That is, the FA OD solution was prepared by dissolving FA 0D derived from Aspergillus' Teleus GP1 (FERli BP-5684) (Aspergillus terreus GPl) in a 0.1 M Tris-HCl buffer (4.0 nit / ml). pH 8.0).
  • FIG. 11 shows the relationship between the * degree and the absorbance of saccharified hemoglobin obtained by this method.
  • the vertical axis in the figure indicates the absorbance at 727 nm (corresponding to the amount of hydrogen peroxide), and the vertical axis indicates the concentration of glycated hemoglobin.
  • the figure shows that there is a correlation between the concentration of glycated hemoglobin and the amount of generated hydrogen peroxide.
  • glycohemoglobin control E (Sigma) was dissolved in 100 1 of distilled water.
  • Acetone hydrochloride (1 N acetone hydrochloride: 1/100) inl was added to these samples, and centrifuged at 12,000 rpm for 10 minutes. The precipitate was washed with getyl ether 500 and dried under reduced pressure.
  • Add 8 ⁇ urea 100 heat in boiling water for 20 minutes, cool and mix with 5.2 units / ml trypsin 300 1 37. I incubated at C for 3 hours. Thereafter, the sample was heated in boiling water for 5 minutes to prepare a sample.
  • the F A 0 D reaction solution was prepared as follows.
  • the 25-unit Zml FAOD solution was prepared by diluting the FAOD obtained by the method of Production Example 4 with 0.1 M potassium phosphate / mouth liquid (pH 7.5) to 25 units / ml.
  • FIG. 12 shows the relationship between the amount of saccharified hemoglobin obtained by this method and the absorbance.
  • the vertical axis in the figure indicates the absorbance at 727 nm (corresponding to the amount of hydrogen peroxide), and the horizontal axis indicates the concentration of saccharified hemoglobin.
  • the figure shows that there is a correlation between the amount of glycated hemoglobin and the hydrogen peroxide generation S.
  • the F A OD reaction solution was prepared as follows.
  • FIG. 13 shows the relationship between the amount of glycated hemoglobin obtained by this method and the absorbance.
  • the vertical axis represents the absorbance at 727 mn (corresponding to the amount of hydrogen peroxide)
  • the horizontal axis represents the concentration of saccharified hemogbin. The figure shows that there is a correlation between the amount of saccharified hemoglobin and the amount of hydrogen peroxide generated.
  • ⁇ Nisylium ⁇ -derived FA ⁇ D obtained by the method described in Production Example 4 was used.
  • Glycohemoglobin controls N and E (Sigma) were dissolved in distilled water.
  • solutions with different hemoglobin A lc values were prepared and assayed using an automatic glycohemoglobin analyzer (Kyoto Daiichi Kagaku). The values were between 5.1% and 9.2%. Met. The following operations were performed using these solutions.
  • the FAOD reaction solution was prepared as follows.
  • the 12 unit / ml FAOD solution was prepared by dissolving the FAOD derived from Penicillium. Chancinerum S—3413 (FESM BP-5475) CPenicillium janthinellum S-3413) obtained in Production Example 4 with 0.1 M phosphoric acid so as to obtain 12 units. It was prepared by diluting with a potassium hydroxide solution (PH7.5).
  • Fig. 14 shows the relationship between the ratio of saccharified amount of palin to the total hemoglobin (vertical axis) and hemoglobin A1c value (horizontal axis) obtained by this method. The figure shows that there is a correlation between the hemoglobin A 1 c value and the glycation ratio of valine in hemoglobin measured using FAOD.
  • Example 15 Measurement of hemoglobin A 1 c value
  • Hemoglobin AO reagent (Sigma) was dissolved in distilled water to 2.3 M. This solution was fractionated using an automatic hemoglobin measuring device (Kyoto Daiichi Kagaku), and the hemoglobin A 1c fraction and the hemoglobin A 0 fraction were separated and purified. Substrate samples with hemoglobin Alc values between 0% and 52.0% were obtained.
  • the FAOD reaction solution was manufactured by IS as follows.
  • the 16-unit Zral FAOD solution was prepared by diluting the FAOD obtained in Production Example 4 with 0.1 M potassium phosphate buffer (pH 7.5) so as to become 16 units-Znl. After 2 minutes Inkyube Bok The FAOD reaction mixture at 30 e C, above the processing solution 400/1 was added, it was measured absorbance at 727nm after incubation for an additional 30 minutes.
  • the relationship between the hemoglobin A 1 c value of the substrate obtained by this method and the substrate is shown in FIG.
  • the vertical axis in the figure represents the absorbance at 727 ⁇ (corresponding to the amount of hydrogen peroxide), and the horizontal axis represents the hemoglobin A 1c value. The figure shows that there is a correlation between hemoglobin A 1 c value and the amount of generated hydrogen peroxide.
  • a platinum working electrode and a silver / silver chloride electrode were used as reference electrodes. These compresses were immersed in a reaction solution obtained by adding 12 units of FADII solution to 5 ml of 0.1 M potassium phosphate buffer solution (pH 7.5).
  • the 12-unit ZoilF AOD solution was prepared by diluting the FAOD derived from Benicillium.Yannnerm S-3413 obtained in Production Example 4 with a 0.1 M potassium phosphate buffer solution (pH 7.5) to 12 units / ml.
  • Fructosyl valine was added to the reaction solution, and the current value was measured at 30 ° C. and a constant voltage of 60 OmV.
  • Figure 16 shows the relationship between the concentration of fructosyl valine obtained by this method and the value of the compress.
  • the vertical axis in the figure indicates the current value (corresponding to the amount of hydrogen peroxide) at a constant voltage of 60 OmV, and the horizontal axis indicates fructosylvaline Ban degree.
  • the figure shows that fructosyl valine and hydrogen peroxide generation are correlated.
  • fructosyl lysine concentration was measured by the following method and the reaction solution
  • Fig. 17 shows the relationship between fructosyl lysine concentration and absorbance obtained by this method.
  • the vertical axis in the figure indicates the absorbance at 555 nro (corresponding to the amount of hydrogen peroxide), and the horizontal axis indicates the fructosyl lysine concentration.
  • the figure shows that there is a correlation between the concentration of fructosyl lysine and the hydrogen peroxide generating children.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé pour doser, par voie enzymatique, des composés d'Amadori dans des compositions biologiques ou dans des aliments, consistant à mesurer la vitesse de saccharification de l'échantillon, à déterminer la quantité de fructosylamine ou à mesurer la concentration de matières saccharifiées.
PCT/JP1996/002964 1995-10-12 1996-10-14 Procede pour doser les composes d'amadori WO1997013872A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP26438795 1995-10-12
JP7/264387 1995-10-12
JP19200396 1996-07-22
JP8/192003 1996-07-22

Publications (1)

Publication Number Publication Date
WO1997013872A1 true WO1997013872A1 (fr) 1997-04-17

Family

ID=26507035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1996/002964 WO1997013872A1 (fr) 1995-10-12 1996-10-14 Procede pour doser les composes d'amadori

Country Status (1)

Country Link
WO (1) WO1997013872A1 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025475A1 (fr) * 1999-10-01 2001-04-12 Kikkoman Corporation Procede d'analyse d'une glycoproteine
WO2002006519A1 (fr) * 2000-07-14 2002-01-24 Arkray, Inc. Procede pour determiner de maniere selective le taux d'hemoglobine glycosylee
WO2003033729A1 (fr) * 2001-10-11 2003-04-24 Arkray, Inc. Procede de pretraitement d'echantillon pour la mesure d'une amine saccharifiee et procede de mesure d'une amine saccharifiee
JP2004222570A (ja) * 2003-01-22 2004-08-12 Asahi Kasei Pharma Kk 糖化タンパク質測定用プロテアーゼ
WO2005087946A1 (fr) * 2004-03-17 2005-09-22 Daiichi Pure Chemicals Co., Ltd. Méthode de mesure des glycoprotéines
WO2006120976A1 (fr) 2005-05-06 2006-11-16 Arkray, Inc. Procede de clivage de proteine et son utilisation
US7250269B2 (en) 2001-01-31 2007-07-31 Asahi Kasei Pharma Corporation Composition for assaying glycoprotein
WO2007125779A1 (fr) 2006-04-25 2007-11-08 Kikkoman Corporation Amadoriase d'eucaryote ayant une stabilite thermique excellente, gene et adn recombinant de l'amadoriase d'eucaryote et procede de production d'une amadoriase d'eucaryote ayant une stabilite thermique excellente
US7329520B2 (en) 2002-10-23 2008-02-12 Daiichi Pure Chemicals Co., Ltd. Fructosyl peptide oxidase and utilization thereof
EP2096173A1 (fr) 2003-05-21 2009-09-02 Asahi Kasei Pharma Corporation Procédé de mesure de l'hémoglobine A1C de glycolate, enzyme à utiliser avec celui-ci et son procédé de production
WO2012018094A1 (fr) 2010-08-06 2012-02-09 キッコーマン株式会社 Amadoriase ayant une spécificité de substrat modifiée
WO2013100006A1 (fr) 2011-12-28 2013-07-04 キッコーマン株式会社 Amadoriase ayant une stabilité thermique améliorée, gène et adn recombinant de celle-ci, et procédé de production d'amadoriase ayant une stabilité thermique améliorée
WO2013162035A1 (fr) 2012-04-27 2013-10-31 キッコーマン株式会社 Amadoriase modifiée capable d'agir sur un hexapeptide de fructosyle
USRE45074E1 (en) 2001-10-11 2014-08-12 Arkray, Inc. Method of pre-treating sample for measuring saccharified amine and method of measuring saccharified amine
WO2015020200A1 (fr) 2013-08-09 2015-02-12 キッコーマン株式会社 AMADORIASE MODIFIÉE ET SON PROCÉDÉ DE PRODUCTION, AGENT PERMETTANT D'AMÉLIORER LA RÉSISTANCE AUX TENSIOACTIFS DE L'AMADORIASE ET COMPOSITION PERMETTANT DE MESURER L'HbA1c À L'AIDE DE CELLE-CI
WO2015060431A1 (fr) 2013-10-25 2015-04-30 キッコーマン株式会社 PROCÉDÉ DE MESURE D'HbA1c À L'AIDE D'AMADORIASE AGISSANT SUR DES PEPTIDES GLYQUÉS
WO2015060429A1 (fr) 2013-10-25 2015-04-30 キッコーマン株式会社 PROCÉDÉ DE MESURE D'HÉMOGLOBINE A1c ET NÉCESSAIRE DE MESURE
KR20170054475A (ko) 2014-10-24 2017-05-17 기꼬만 가부시키가이샤 디히드로게나아제 활성이 향상된 아마도리아제
US9708586B2 (en) 2010-08-06 2017-07-18 Kikkoman Corporation Amadoriase having altered substrate specificity
WO2019045052A1 (fr) 2017-08-31 2019-03-07 キッコーマン株式会社 Variant d'hémoglobine oxydase glyquée et procédé de mesure
WO2021002371A1 (fr) 2019-07-01 2021-01-07 旭化成ファーマ株式会社 Réactif de dosage de protéine glycosylée contenant un stabilisant de protéase augmentant le potentiel redox de ferrocyanure, procédé de dosage de protéine glycosylée, procédé de conservation de réactif de dosage de protéine glycosylée, et procédé de stabilisation de réactif de dosage de protéine glycosylée
US10934530B2 (en) 2015-04-03 2021-03-02 Kikkoman Corporation Amadoriase having improved specific activity
US11111517B2 (en) 2016-04-22 2021-09-07 Kikkoman Corporation HbA1c dehydrogenase
US11198852B2 (en) 2014-11-07 2021-12-14 Kikkoman Corporation Amadoriase having enhanced anionic surfactant tolerance
US11384381B2 (en) 2016-07-13 2022-07-12 Kikkoman Corporation Reaction accelerating agent

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280297A (ja) * 1985-06-04 1986-12-10 Noda Sangyo Kagaku Kenkyusho アマドリ化合物の定量法及びその定量用試薬
JPH03155780A (ja) * 1989-11-14 1991-07-03 Noda Sangyo Kagaku Kenkyusho フルクトシルアミン・オキシダーゼ、その製造法、該酵素を用いたアマドリ化合物の定量法及びその試薬
JPH044874A (ja) * 1990-04-20 1992-01-09 Nakano Vinegar Co Ltd フラクトシルアミノ酸分解酵素、その製造法及びその利用
JPH05192193A (ja) * 1991-07-29 1993-08-03 Genzyme Ltd 非酵素的グリコシル化タンパク質の検定法
JPH0646846A (ja) * 1992-06-05 1994-02-22 Nakano Vinegar Co Ltd フルクトシルアミンデグリカーゼ、その製造法及び該酵素を用いたアマドリ化合物の定量方法
JPH07289253A (ja) * 1994-03-03 1995-11-07 Kyoto Daiichi Kagaku:Kk フルクトシルアミノ酸オキシダーゼ及びその製造方法
JPH08154672A (ja) * 1994-10-05 1996-06-18 Kdk Corp フルクトシルアミノ酸オキシダーゼ及びその製造方法
JPH08336386A (ja) * 1995-04-11 1996-12-24 Kdk Corp フルクトシルアミノ酸オキシダーゼおよびその製造方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280297A (ja) * 1985-06-04 1986-12-10 Noda Sangyo Kagaku Kenkyusho アマドリ化合物の定量法及びその定量用試薬
JPH03155780A (ja) * 1989-11-14 1991-07-03 Noda Sangyo Kagaku Kenkyusho フルクトシルアミン・オキシダーゼ、その製造法、該酵素を用いたアマドリ化合物の定量法及びその試薬
JPH044874A (ja) * 1990-04-20 1992-01-09 Nakano Vinegar Co Ltd フラクトシルアミノ酸分解酵素、その製造法及びその利用
JPH05192193A (ja) * 1991-07-29 1993-08-03 Genzyme Ltd 非酵素的グリコシル化タンパク質の検定法
JPH0646846A (ja) * 1992-06-05 1994-02-22 Nakano Vinegar Co Ltd フルクトシルアミンデグリカーゼ、その製造法及び該酵素を用いたアマドリ化合物の定量方法
JPH07289253A (ja) * 1994-03-03 1995-11-07 Kyoto Daiichi Kagaku:Kk フルクトシルアミノ酸オキシダーゼ及びその製造方法
JPH08154672A (ja) * 1994-10-05 1996-06-18 Kdk Corp フルクトシルアミノ酸オキシダーゼ及びその製造方法
JPH08336386A (ja) * 1995-04-11 1996-12-24 Kdk Corp フルクトシルアミノ酸オキシダーゼおよびその製造方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Vol. 61, No. 12, (December 1995) YOSHIDA N. et al., "Distribution and Properties of Fructosyl Amino Acid Oxidase in Fungi", pages 4487-4489. *
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, Vol. 61, No. 1, (January 1996), SAKAI Y. et al., "Production of Fructosyl Lysine Oxidase from Fusarium Oxysporum S-1F4 on Autoclave-Browned Medium", pages 150-151. *
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMSTRY, Vol. 59, No. 3, (March 1995) SAKAI Y. et al., "Purification and Properties of Fructosyl Lysine Oxidase From Fusarium Oxysporum S-1F4", pages 487-491. *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025475A1 (fr) * 1999-10-01 2001-04-12 Kikkoman Corporation Procede d'analyse d'une glycoproteine
US7070948B1 (en) 1999-10-01 2006-07-04 Kikkoman Corporation Method for assaying glycated protein
USRE46118E1 (en) 2000-07-14 2016-08-23 Arkray, Inc. Method of selectively determining glycated hemoglobin
WO2002006519A1 (fr) * 2000-07-14 2002-01-24 Arkray, Inc. Procede pour determiner de maniere selective le taux d'hemoglobine glycosylee
CN101875963B (zh) * 2000-07-14 2013-10-16 爱科来株式会社 糖基化血红蛋白的选择性测定方法
EP2944699A1 (fr) * 2000-07-14 2015-11-18 ARKRAY, Inc. Procede permettant de determiner de maniere selective l'hemoglobine glyquee
CN101363044B (zh) * 2000-07-14 2013-01-09 爱科来株式会社 糖基化血红蛋白的选择性测定方法
US7235378B2 (en) 2000-07-14 2007-06-26 Arkray, Inc. Method of selectively determining glycated hemoglobin
USRE46105E1 (en) 2000-07-14 2016-08-16 Arkray, Inc. Method of selectively determining glycated hemoglobin
USRE46130E1 (en) 2000-07-14 2016-08-30 Arkray, Inc. Method of selectively determining glycated hemoglobin
EP2336351A3 (fr) * 2000-07-14 2011-09-14 Arkray, Inc. Procédé pour déterminer de manière sélective d'hémoglobine glyquée
US7250269B2 (en) 2001-01-31 2007-07-31 Asahi Kasei Pharma Corporation Composition for assaying glycoprotein
US8105800B2 (en) 2001-01-31 2012-01-31 Asahi Kasei Pharma Corporation Composition for assaying glycated proteins
EP2107376A2 (fr) 2001-01-31 2009-10-07 Asahi Kasei Pharma Corporation Composition d'analyse des protéines glyquées
EP2107123A2 (fr) 2001-01-31 2009-10-07 Asahi Kasei Pharma Corporation Composition d'analyse des protéines glyquées
EP2236618A2 (fr) 2001-01-31 2010-10-06 Asahi Kasei Pharma Corporation Compositions pour analyser une glycoprotéine
EP2248909A1 (fr) 2001-01-31 2010-11-10 Asahi Kasei Pharma Corporation Composition d'analyse des protéines glyquées
WO2003033729A1 (fr) * 2001-10-11 2003-04-24 Arkray, Inc. Procede de pretraitement d'echantillon pour la mesure d'une amine saccharifiee et procede de mesure d'une amine saccharifiee
USRE45626E1 (en) 2001-10-11 2015-07-28 Arkray, Inc. Method of pre-treating sample for measuring saccharified amine and method of measuring saccharified amine
USRE46073E1 (en) 2001-10-11 2016-07-19 Arkray, Inc. Method of pre-treating sample for measuring saccharified amine and method of measuring saccharified amine
USRE43795E1 (en) 2001-10-11 2012-11-06 Arkray, Inc. Method of pre-treating sample for measuring saccharified amine and method of measuring saccharified amine
USRE45074E1 (en) 2001-10-11 2014-08-12 Arkray, Inc. Method of pre-treating sample for measuring saccharified amine and method of measuring saccharified amine
US7449305B2 (en) 2001-10-11 2008-11-11 Arkray, Inc. Method of pre-treating sample for measuring saccharified amine and method of measuring saccharified amine
US7329520B2 (en) 2002-10-23 2008-02-12 Daiichi Pure Chemicals Co., Ltd. Fructosyl peptide oxidase and utilization thereof
US7393549B2 (en) 2002-10-23 2008-07-01 Daiichi Pure Chemicals Co., Ltd. Defructosylation method
JP2004222570A (ja) * 2003-01-22 2004-08-12 Asahi Kasei Pharma Kk 糖化タンパク質測定用プロテアーゼ
US7943337B2 (en) 2003-05-21 2011-05-17 Asahi Kasei Pharma Corporation Method for screening a protease
US7588910B2 (en) 2003-05-21 2009-09-15 Asahi Kasei Pharma Corporation Hemoglobin A1c determination method, enzyme to be used therefor, and production method thereof
EP2096173A1 (fr) 2003-05-21 2009-09-02 Asahi Kasei Pharma Corporation Procédé de mesure de l'hémoglobine A1C de glycolate, enzyme à utiliser avec celui-ci et son procédé de production
WO2005087946A1 (fr) * 2004-03-17 2005-09-22 Daiichi Pure Chemicals Co., Ltd. Méthode de mesure des glycoprotéines
US7820404B2 (en) 2005-05-06 2010-10-26 Arkray, Inc. Protein cleavage method and use thereof
WO2006120976A1 (fr) 2005-05-06 2006-11-16 Arkray, Inc. Procede de clivage de proteine et son utilisation
US8828699B2 (en) 2006-04-25 2014-09-09 Kikkoman Corporation Eukaryotic amadoriase, gene and recombinant DNA for the eukaryotic amadoriase, and process for production of the eukaryotic amadoriase
EP2520650A2 (fr) 2006-04-25 2012-11-07 Kikkoman Corporation Amadoriase eucaryote ayant une stabilité thermique excellente, gène et ADN recombinant de l'amadoriase eucaryote et procédé de production d'une amadoriase eucaryote ayant une stabilité thermique excellente
WO2007125779A1 (fr) 2006-04-25 2007-11-08 Kikkoman Corporation Amadoriase d'eucaryote ayant une stabilite thermique excellente, gene et adn recombinant de l'amadoriase d'eucaryote et procede de production d'une amadoriase d'eucaryote ayant une stabilite thermique excellente
US8003359B2 (en) 2006-04-25 2011-08-23 Kikkoman Corporation Eukaryotic amadoriase having excellent thermal stability, gene and recombinant DNA for the eukaryotic amadoriase, and process for production of eukaryotic amadoriase having excellent thermal stability
US9708586B2 (en) 2010-08-06 2017-07-18 Kikkoman Corporation Amadoriase having altered substrate specificity
US9062286B2 (en) 2010-08-06 2015-06-23 Kikkoman Corporation Amadoriase having altered substrate specificity
KR20130105614A (ko) 2010-08-06 2013-09-25 기꼬만 가부시키가이샤 기질 특이성이 개변된 아마드리아제
WO2012018094A1 (fr) 2010-08-06 2012-02-09 キッコーマン株式会社 Amadoriase ayant une spécificité de substrat modifiée
US9701949B2 (en) 2011-12-28 2017-07-11 Kikkoman Corporation Amadoriase with improved thermostability, gene and recombinant DNA for the amadoriase, and method for production of amadoriase with improved thermostability
WO2013100006A1 (fr) 2011-12-28 2013-07-04 キッコーマン株式会社 Amadoriase ayant une stabilité thermique améliorée, gène et adn recombinant de celle-ci, et procédé de production d'amadoriase ayant une stabilité thermique améliorée
WO2013162035A1 (fr) 2012-04-27 2013-10-31 キッコーマン株式会社 Amadoriase modifiée capable d'agir sur un hexapeptide de fructosyle
EP3508577A2 (fr) 2012-04-27 2019-07-10 Kikkoman Corporation Amadoriase modifiée capable d'agir sur un hexapeptide de fructosyle
US10767211B2 (en) 2012-04-27 2020-09-08 Kikkoman Corporation Modified amadoriase reacting with fructosyl hexapeptide
WO2015020200A1 (fr) 2013-08-09 2015-02-12 キッコーマン株式会社 AMADORIASE MODIFIÉE ET SON PROCÉDÉ DE PRODUCTION, AGENT PERMETTANT D'AMÉLIORER LA RÉSISTANCE AUX TENSIOACTIFS DE L'AMADORIASE ET COMPOSITION PERMETTANT DE MESURER L'HbA1c À L'AIDE DE CELLE-CI
US11549134B2 (en) 2013-08-09 2023-01-10 Kikkoman Corporation Modified amadoriase and method for producing the same, agent for improving surfactant resistance of amadoriase and composition for measuring HbA1c using the same
US10619183B2 (en) 2013-08-09 2020-04-14 Kikkoman Corporation Modified amadoriase and method for producing the same, agent for improving surfactant resistance of amadoriase and composition for measuring HbA1c using the same
EP3760717A1 (fr) 2013-08-09 2021-01-06 Kikkoman Corporation Amadoriase modifiée et son procédé de production, agent permettant d'améliorer la résistance aux tensioactifs de l'amadoriase et composition permettant de mesurer l'hba1c à l'aide de celle-ci
WO2015060429A1 (fr) 2013-10-25 2015-04-30 キッコーマン株式会社 PROCÉDÉ DE MESURE D'HÉMOGLOBINE A1c ET NÉCESSAIRE DE MESURE
WO2015060431A1 (fr) 2013-10-25 2015-04-30 キッコーマン株式会社 PROCÉDÉ DE MESURE D'HbA1c À L'AIDE D'AMADORIASE AGISSANT SUR DES PEPTIDES GLYQUÉS
US11078517B2 (en) 2013-10-25 2021-08-03 Kikkoman Corporation Hemoglobin A1c measurement method and measurement kit
US10697979B2 (en) 2013-10-25 2020-06-30 Kikkoman Corporation Method for measurement of HbA1c using amadoriase that reacts with glycated peptide
US11499143B2 (en) 2014-10-24 2022-11-15 Kikkoman Corporation Amadoriase having enhanced dehydrogenase activity
EP3786291A1 (fr) 2014-10-24 2021-03-03 Kikkoman Corporation Amadoriase ayant une activité de déshydrogénase améliorée
KR20170054475A (ko) 2014-10-24 2017-05-17 기꼬만 가부시키가이샤 디히드로게나아제 활성이 향상된 아마도리아제
US11198852B2 (en) 2014-11-07 2021-12-14 Kikkoman Corporation Amadoriase having enhanced anionic surfactant tolerance
US10934530B2 (en) 2015-04-03 2021-03-02 Kikkoman Corporation Amadoriase having improved specific activity
US11111517B2 (en) 2016-04-22 2021-09-07 Kikkoman Corporation HbA1c dehydrogenase
US11384381B2 (en) 2016-07-13 2022-07-12 Kikkoman Corporation Reaction accelerating agent
WO2019045052A1 (fr) 2017-08-31 2019-03-07 キッコーマン株式会社 Variant d'hémoglobine oxydase glyquée et procédé de mesure
US12258589B2 (en) 2017-08-31 2025-03-25 Kikkoman Corporation Glycated hemoglobin oxidase variant and method for measurement
KR20220011699A (ko) 2019-07-01 2022-01-28 아사히 가세이 파마 가부시키가이샤 페로시안화물의 산화 환원 전위를 크게 하는 프로테아제의 안정화제를 포함하는 당화 단백질 측정 시약, 당화 단백질의 측정 방법, 당화 단백질 측정 시약의 보존 방법, 및 당화 단백질 측정 시약의 안정화 방법
WO2021002371A1 (fr) 2019-07-01 2021-01-07 旭化成ファーマ株式会社 Réactif de dosage de protéine glycosylée contenant un stabilisant de protéase augmentant le potentiel redox de ferrocyanure, procédé de dosage de protéine glycosylée, procédé de conservation de réactif de dosage de protéine glycosylée, et procédé de stabilisation de réactif de dosage de protéine glycosylée

Similar Documents

Publication Publication Date Title
WO1997013872A1 (fr) Procede pour doser les composes d'amadori
AU655646B2 (en) A method for the determination of glycated proteins in biological material
JP4061348B2 (ja) 糖化タンパク質の酵素的測定方法
JP3850904B2 (ja) フルクトシルアミノ酸オキシダーゼ及びその製造方法
JP4227820B2 (ja) 新規な酵素
US5712138A (en) Fructosyl amino acid oxidase
JP3786966B2 (ja) フルクトシルアミノ酸オキシダーゼ、その製造方法、及び該酵素を用いたアマドリ化合物の測定方法
JP2923222B2 (ja) フルクトシルアミノ酸オキシダーゼ及びその製造方法
JPH0646846A (ja) フルクトシルアミンデグリカーゼ、その製造法及び該酵素を用いたアマドリ化合物の定量方法
JP2001095598A (ja) 糖化蛋白質の測定方法
JP4004081B2 (ja) フルクトシルアミノ酸オキシダーゼおよびその製造方法
EP0678576A2 (fr) Fructosyl amino acide oxidase et procédé pour sa préparation
EP0737744B1 (fr) Fructosyl amino acide oxidase et procédé pour sa préparation
US5985591A (en) Method for the determination of glycosylated proteins
EP0264815B1 (fr) Procédés pour la mesure sélective des aminoacides
JP3416540B2 (ja) フルクトシルアミノ酸オキシダーゼ及びその製造方法
EP0806482A2 (fr) Méthode pour l'analyse enzymatique et réactif pour cette méthode
JP2003169696A (ja) 生体成分の測定方法およびそれに用いる試薬組成物
JP2004344052A (ja) ヘモグロビンＡ１ｃ測定用プロテアーゼ
KR890002412B1 (ko) L-글루타민산 옥시다아제의 제조법
JPH11196897A (ja) 糖化タンパク質の測定方法及び測定装置
JPH04278098A (ja) カンジダ症の検出方法及びキット
CN1161374A (zh) 果糖氨基酸氧化酶及其生产方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase